Viking Therapeutics Unveils Phase 3 Clinical Program for VK2735
Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical company invested in developing novel therapies, recently announced an exciting milestone: the initiation of its Phase 3 clinical program for VK2735, a dual agonist targeting the GLP-1 and GIP receptors. This innovative therapy is under evaluation for its potential to combat obesity, both in individuals living with and without Type 2 diabetes.
Overview of the VANQUISH Phase 3 Clinical Trials
The VANQUISH program comprises two pivotal studies: VANQUISH-1 and VANQUISH-2, both designed to assess the efficacy and safety of VK2735. Each trial will employ a randomized, double-blind, placebo-controlled design across multiple centers, focusing on the subcutaneous administration of VK2735 once a week over a period of 78 weeks.
VANQUISH-1 aims to recruit around 4,500 adult participants with obesity (BMI ?30 kg/m2) or overweight (BMI ?27 kg/m2) who also present at least one weight-related health condition. Meanwhile, VANQUISH-2 will focus on approximately 1,100 adults diagnosed with Type 2 diabetes who are either obese or overweight.
Trial Objectives and Endpoints
The primary goal of these trials is to evaluate the percentage change in body weight from baseline among participants receiving VK2735, compared to those on placebo, after the completion of treatment. Additionally, the studies will explore secondary endpoints, which include the attainment of various body weight reduction milestones—specifically, reductions of ?5%, ?10%, ?15%, and ?20% from baseline.
Each trial will also incorporate an open-label extension, allowing participants to continue receiving VK2735 after the initial dosing period concludes, thereby providing further insights into the long-term efficacy and safety of the treatment.
Exciting Development by Viking Therapeutics
Viking Therapeutics' CEO, Brian Lian, Ph.D., expressed exhilaration about advancing VK2735 into Phase 3 development, highlighting its significance for patients struggling with obesity. He also mentioned ongoing efforts with plans to start an additional study later this year to evaluate a monthly maintenance regimen of VK2735.
Further, Viking is building on encouraging preliminary data from the oral formulation of VK2735, with results from the Phase 2 VENTURE-Oral Dosing study expected to be announced in the near future.
Previous Study Success: VENTURE Trial Results
In recent developments, Viking Therapeutics revealed positive results from its Phase 2 VENTURE study, which evaluated subcutaneous VK2735 for obesity management. This pivotal trial not only achieved its primary endpoint but also exceeded secondary objectives, showcasing VK2735's strong potential in generating significant reductions in body weight as compared to placebo.
Patients treated with VK2735 experienced meaningful reductions in mean body weight from baseline, achieving reductions of up to 14.7%, as well as statistically significant differences—from the first week—relative to placebo throughout the study duration. Notably, follow-up assessments indicated that participants maintained most of their weight loss even several weeks after the final dose.
Safety and Tolerability Findings
The safety profile of VK2735, demonstrated in the VENTURE study, was reassuring, with most adverse events being mild to moderate in nature. Treatment discontinuation rates for VK2735 participants were comparable to those in the placebo group, suggesting that the treatment remained well tolerated.
While certain gastrointestinal issues were reported, they were predominantly mild or moderate, with the majority of such side effects occurring during the initial treatment week.
Understanding GLP-1 and Dual Agonist Therapies
At the core of VK2735's therapeutic approach is the activation of the GLP-1 receptor, known to reduce glucose levels, curb appetite, and foster weight loss while enhancing insulin sensitivity. Notably, other GLP-1 receptor agonists, like semaglutide, have received FDA approval and are available in various forms for managing similar indications.
The recent exploration into dual receptor agonists, like tirzepatide, seeks to amplify the therapeutic effects afforded by GLP-1 activation, potentially offering greater benefits to patients struggling with metabolic challenges.
About Viking Therapeutics, Inc.
Viking Therapeutics is committed to developing innovative first-in-class or best-in-class therapies aimed at addressing metabolic and endocrine disorders. With a multitude of programs currently in clinical trial stages, the company leans on its extensive expertise in metabolism to pioneer therapeutics designed to enhance patients’ wellbeing. Beyond VK2735, Viking is investigating VK2809, an oral selective thyroid hormone receptor beta agonist, and innovative dual amylin and calcitonin receptor agonists, alongside efforts in rare diseases like X-linked adrenoleukodystrophy (X-ALD).
For more information, visit www.vikingtherapeutics.com.
Frequently Asked Questions
What is VK2735?
VK2735 is a dual agonist that targets GLP-1 and GIP receptors, developed by Viking Therapeutics for managing obesity and related metabolic disorders.
What are the main goals of the VANQUISH Phase 3 trials?
The trials aim to assess the efficacy and safety of VK2735 in reducing body weight among adults with obesity and Type 2 diabetes.
How many participants are involved in the VANQUISH studies?
Approximately 5,600 participants combined will be enrolled across both trials.
What results did the VENTURE trial yield?
The VENTURE trial showed positive results, with VK2735 demonstrating significant reductions in body weight compared to placebo.
What are the potential benefits of GLP-1/GIP dual agonists?
These dual agonists may enhance weight loss, improve glucose control, and provide better insulin sensitivity in patients with metabolic disorders.
